

Jean-Philippe Vuillez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3039158/publications.pdf>

Version: 2024-02-01

34
papers

1,107
citations

516710

16
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

1087
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti- α -Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711. | 1.6 | 231 |
| 2 | Fluorinated tracers for imaging cancer with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1182-206. | 6.4 | 116 |
| 3 | Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597. | 3.6 | 89 |
| 4 | Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and ^{131}I -labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55. | 5.0 | 88 |
| 5 | Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192. | 5.0 | 74 |
| 6 | Pretargeting with the Affinity Enhancement System for Radioimmunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1999, 14, 153-166. | 1.0 | 65 |
| 7 | Intrapleural Infusion of Activated Macrophages and I^3 -Interferon in Malignant Pleural Mesothelioma. <i>Chest</i> , 2002, 121, 1921-1927. | 0.8 | 62 |
| 8 | In vivo imaging of tumour angiogenesis in mice with the I^2I^3 integrin-targeted tracer $^{99\text{m}}\text{Tc}$ -RAFT-RGD. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 2037-2047. | 6.4 | 62 |
| 9 | Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1212-1217. | 5.0 | 36 |
| 10 | Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 758-764. | 6.4 | 33 |
| 11 | Consolidation anti-CD22 fractionated radioimmunotherapy with ^{90}Y -epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45. | 4.6 | 33 |
| 12 | Effects of preoperative intentional hemodilution on the extravasation rate of albumin and fluid. <i>Critical Care Medicine</i> , 1997, 25, 243-248. | 0.9 | 29 |
| 13 | Chemical and Biological Evaluations of an ^{111}In -Labeled RGD-Peptide Targeting Integrin Alpha(V) Beta(3) in a Preclinical Tumor Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 691-700. | 1.0 | 18 |
| 14 | Reduction of renal uptake of ^{111}In -DOTA-labeled and ^{111}In -RAFT-RGD during integrin I^2V^3 targeting using single photon emission computed tomography and optical imaging. <i>Cancer Science</i> , 2012, 103, 1105-1110. | 3.9 | 17 |
| 15 | Adjuvant Intraarterial Lipiodol or ^{131}I -Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. <i>Journal of Nuclear Medicine</i> , 2014, 55, 877-883. | 5.0 | 17 |
| 16 | Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices. <i>Annales D'Endocrinologie</i> , 2014, 75, 241-246. | 1.4 | 17 |
| 17 | ^{18}F -FLT and ^{18}F -FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours. <i>Nuclear Medicine Communications</i> , 2011, 32, 91-97. | 1.1 | 15 |
| 18 | ^{18}F -FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510. | 6.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 8-11. | 6.4 | 11 |
| 20 | FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Brazilian Archives of Biology and Technology, 2007, 50, 77-90. | 0.5 | 10 |
| 21 | Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?. Cancer Imaging, 2020, 20, 58. | 2.8 | 10 |
| 22 | Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. Blood, 2010, 116, 2875-2875. | 1.4 | 10 |
| 23 | Study of inter- and intra-observer reproducibility in the interpretation of [18F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment. EJNMMI Research, 2014, 4, 25. | 2.5 | 9 |
| 24 | 18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, e471-e472. | 1.3 | 7 |
| 25 | Sentinel lymph node biopsy in cutaneous melanoma: outcome after 5-years follow-up. European Journal of Dermatology, 2007, 17, 387-91. | 0.6 | 6 |
| 26 | Neopterin Levels in Plasma during a Longitudinal Study in an Area Endemic for Malaria. Clinical Immunology and Immunopathology, 1993, 67, 273-276. | 2.0 | 5 |
| 27 | Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy. Nephrology Dialysis Transplantation, 2009, 24, 2598-2600. | 0.7 | 5 |
| 28 | Nuclear medicine training and practice in France. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 976-978. | 6.4 | 5 |
| 29 | Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906. | 1.4 | 5 |
| 30 | Cellular uptake of 99mTcN-NOET in human leukaemic HL-60 cells is related to calcium channel activation and cell proliferation. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 66-72. | 6.4 | 4 |
| 31 | Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy, 2013, 5, 1283-1286. | 2.0 | 3 |
| 32 | Survival and prognostic factors after adjuvant 131Iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. Annals of Nuclear Medicine, 2017, 31, 379-389. | 2.2 | 1 |
| 33 | In-111 Pentetreotide Scintigraphy to Monitor Nonsecreting Neuroendocrine Tumors. Clinical Nuclear Medicine, 1999, 24, 459-460. | 1.3 | 0 |
| 34 | PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007. Blood, 2015, 126, 3932-3932. | 1.4 | 0 |